Fiscal Year Ending September 2026 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Results

In this fiscal year, consolidated net sales decreased from 64,724 million yen to 62,651 million yen, with all segments including cosmetics, pharmaceuticals, food, and others recording lower sales. Operating income decreased to 9,424 million yen year-on-year, ordinary income was 9,896 million yen, and net income was 8,216 million yen (Year-over-Year +2.3%), with net income attributable to owners of parent reaching a record high. The financial position remains solid with an equity ratio of 71.8%. The company maintains a stable dividend policy with a year-end dividend of 232 yen per share. For the next fiscal year, the company forecasts net sales of 643 hundred million yen, operating income of 104 hundred million yen, ordinary income of 108 hundred million yen, and net income of 83 hundred million yen.

Outlook and Impact on Shareholders

Amid economic recovery, there is a downside risk to personal consumption from price increases, but the group will promote sustainable management across its businesses. Under the medium- to long-term strategy, the consolidated targets for the fiscal year ending September 2027 are net sales of 643 hundred million yen, operating income of 104 hundred million yen, ordinary income of 108 hundred million yen, and net income attributable to owners of parent of 83 hundred million yen. The company plans to maintain the annual dividend of 232 yen per share and continue its policy of increasing dividends.